Daily Stock Market News

Intercept Pharmaceutical Stock Sees RS Rating Rise To 91

When looking for the best stocks to buy and watch, focus on those with rising relative price strength.

One stock that fits that bill is Intercept Pharmaceutical (ICPT) stock, which saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, rising from 80 to 91.


When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. This unique rating identifies market leadership by showing how a stock’s price action over the last 52 weeks measures up against that of the other stocks in our database.

Decades of market research reveals that the top-performing stocks tend to have an RS Rating of above 80 as they launch their biggest runs.

Looking For The Best Stocks To Buy And Watch? Start Here

Intercept Pharmaceutical Stock A Buy?

While it’s not currently an ideal time to buy shares of Intercept Pharmaceutical stock, see if the stock is able to establish and enter a buy zone in heavy trade. Look for the stock market outlook to rally in a confirmed uptrend before adding stocks.

Earnings grew 10% last quarter, up from 0% in the prior report. Revenue also increased, from 3% to 5%.

Intercept Pharmaecutical stock holds the No. 100 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharma (CPRX), Vertex Pharmaceuticals (VRTX) and Amphastar Pharmaceutcls (AMPH) are among the top 5 highly rated stocks within the group. For more industry news, check out “Biotech And Pharmaceutical Industry And Stock News.”


MarketSmith’s Tools Can Help The Individual Investor

IBD Live: A New Tool For Daily Stock Market Analysis

Profit From Short-Term Trends With SwingTrader

How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks


Read More: Intercept Pharmaceutical Stock Sees RS Rating Rise To 91

You might also like
A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.